
GLP-1 and SGLT2: a US review highlights persistent inequalities in access
A review of 100 US studies describes gaps in access to GLP-1 agonists and SGLT2 inhibitors, without quantifying their magnitude in the available abstract.
Read the newsRecent studies and announcements, explained with the same rigor as our analyses: sources, context, and the limitations of the data.

A review of 100 US studies describes gaps in access to GLP-1 agonists and SGLT2 inhibitors, without quantifying their magnitude in the available abstract.
Read the news
A review of 92 trials suggests benefits of digital care for pain and functional limitations, but the evidence remains weak.

A review of 18 studies reports encouraging performance in mental health screening, but heterogeneous methods limit the conclusions.

A meta-analysis of five trials shows a substantial reduction in LDL with oral PCSK9 inhibitors, without establishing which treatment is superior.

An analysis of BrainFit-Nutrition observes a reduction in alcohol consumption at 12 months in two nutritional counseling groups, without establishing a cognitive benefit.